GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » ROE %

Kindstar Globalgene Technology (HKSE:09960) ROE % : 0.82% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Kindstar Globalgene Technology's annualized net income for the quarter that ended in Jun. 2024 was HK$26 Mil. Kindstar Globalgene Technology's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was HK$3,129 Mil. Therefore, Kindstar Globalgene Technology's annualized ROE % for the quarter that ended in Jun. 2024 was 0.82%.

The historical rank and industry rank for Kindstar Globalgene Technology's ROE % or its related term are showing as below:

HKSE:09960' s ROE % Range Over the Past 10 Years
Min: -311.04   Med: 1.43   Max: 2.6
Current: 0.31

During the past 6 years, Kindstar Globalgene Technology's highest ROE % was 2.60%. The lowest was -311.04%. And the median was 1.43%.

HKSE:09960's ROE % is ranked better than
54.59% of 207 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.93 vs HKSE:09960: 0.31

Kindstar Globalgene Technology ROE % Historical Data

The historical data trend for Kindstar Globalgene Technology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology ROE % Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - - -311.04 2.60 1.43

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.41 0.89 3.03 -0.19 0.82

Competitive Comparison of Kindstar Globalgene Technology's ROE %

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's ROE % distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's ROE % falls into.


;
;

Kindstar Globalgene Technology ROE % Calculation

Kindstar Globalgene Technology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=45.158/( (3156.414+3141.324)/ 2 )
=45.158/3148.869
=1.43 %

Kindstar Globalgene Technology's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=25.61/( (3141.324+3116.325)/ 2 )
=25.61/3128.8245
=0.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Kindstar Globalgene Technology  (HKSE:09960) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=25.61/3128.8245
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(25.61 / 1019.132)*(1019.132 / 4067.8435)*(4067.8435 / 3128.8245)
=Net Margin %*Asset Turnover*Equity Multiplier
=2.51 %*0.2505*1.3001
=ROA %*Equity Multiplier
=0.63 %*1.3001
=0.82 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=25.61/3128.8245
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (25.61 / 32.444) * (32.444 / -37.25) * (-37.25 / 1019.132) * (1019.132 / 4067.8435) * (4067.8435 / 3128.8245)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7894 * -0.871 * -3.66 % * 0.2505 * 1.3001
=0.82 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Kindstar Globalgene Technology ROE % Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindstar Globalgene Technology Business Description

Traded in Other Exchanges
N/A
Address
Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.
Executives
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited 2101 Beneficial owner
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Huang Shiang 2101 Beneficial owner
Tu Zanbing
Huang Zuie-chin 2101 Beneficial owner
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Jackson Hole Trust Company
Huang Bo
Kernelstar Limited 2301 Trustee
Kastle Limited 2301 Trustee
Guo Gui-rong 2202 Interest of your spouse
Morningside Holdings (asia) Limited 2201 Interest of corporation controlled by you

Kindstar Globalgene Technology Headlines

No Headlines